Pharma
Flare Capital's Alexandra Mullin and Ian Chiang outline COVID-19's impact on the worsening opioid crisis and how the digital opioid use disorder space is likely to develop over the coming years.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.
The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry.
This special collection, which will be updated throughout the month, looks at what's being done to ease the provider burden.
The results will not impact the current rollout of a new version of the app, under special FDA guidelines.
The research project will be conducted using the Apple Watch and iPhone, and is set to begin during 2021.
The Cairo-based health tech startup’s founder revealed plans for the company’s expansion, with “an aggressive plan to cover MENA and Africa in the foreseeable future.”
Medidata said the deal will help better integrate clinical-grade metrics into its remote trial platform and broadly support the use of wearable sensors for clinical research.
The yet-to-be-named programme reportedly “leverages machine learning to optimise a clinical trial’s chances of success” through the analysis of factors such as patient population recruitment and dropout rate.